Statement From: Martin A Makary, M.D., M.P.H. Commissioner of Food and Drugs - Food and Drug Administration The U.S. Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies — including Hims...
Autoimmune diseases occur when the immune system mistakenly attacks healthy tissues. Conditions like lupus, rheumatoid arthritis, type 1 diabetes, and multiple sclerosis can be chronic, painful, and difficult to treat. For many years, doctors have mostly relied on broad immunosuppression — drugs that reduce immune system activity overall. But newer approaches aim to...
Many people with type 2 diabetes take medications after metformin to control blood sugar, but not all of those drugs behave the same in the body. A large real-world study published in JAMA Network Open looked at whether three common diabetes medicines affect the risk of serious heart problems like heart attack, stroke, heart failure, or heart-related death.
The bottom line:
This study doesn’t prove cause and effect for every individual, but it adds strong real-world evidence that the choice of diabetes medicine can influence heart health.
Beware of products claiming to cure cancer on websites or social media platforms, such as Facebook and Instagram. According to Nicole Kornspan, M.P.H., a consumer safety officer at the U.S. Food and Drug Administration (FDA), they’re rampant these days. “Anyone who suffers from cancer, or knows someone who does, understands the fear and desperation that can set in,”...
As people get older, their risk of heart disease tends to rise. Doctors usually look at things like blood pressure, cholesterol, and lifestyle to estimate that risk. But scientists are also searching for biological markers—substances in the blood that might help identify who is most likely to develop heart problems. A new study found that both vitamin D levels and a...
Triple-negative breast cancer (TNBC) is one of the most aggressive and hard-to-treat forms of breast cancer. It tends to grow quickly and has limited treatment options, especially once the disease is advanced or has spread to other parts of the body. Recently published results from a major phase 3 clinical trial show that combining two cancer drugs — sacituzumab...